Chargement en cours...
First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence
BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is an effective treatment for advanced lung cancer harboring EGFR gene mutations, and has improved progression-free survival in several clinical trials. METHODS: We investigated 30 stage I non-small-cell lung can...
Enregistré dans:
| Publié dans: | Cancer Manag Res |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7899306/ https://ncbi.nlm.nih.gov/pubmed/33628055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S292295 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|